Nexus Pharmaceuticals
  • Home
  • Our Company
    • About Us
    • Focus and Responsibility
    • Commitment to Quality
    • Team and Culture
  • Products
  • Careers
  • News
    • Latest News
    • State-of-the- Art Manufacturing Facility
  • Contact Us
Select Page
Nexus Pharmaceuticals Discusses COVID-19 Response in BioForward Webinar

Nexus Pharmaceuticals Discusses COVID-19 Response in BioForward Webinar

by Deana Mndrucic | Jan 27, 2021 | News

PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Chief Strategy Officer, Omair Ahmed, joined nine BioForward member organizations in a discussion regarding the Wisconsin biohealth industry’s response to the COVID-19 pandemic. “We pride ourselves in...
Nexus Pharmaceuticals Discusses COVID-19 Response in BioForward Webinar

Nexus Pharmaceuticals sets month for $100M plant opening, preps drug for treating Covid patients

by Deana Mndrucic | Dec 21, 2020 | News

PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers...
Nexus Pharmaceuticals Discusses COVID-19 Response in BioForward Webinar

Nexus Pharmaceuticals Announces Diversity Certification

by Deana Mndrucic | Dec 3, 2020 | News

LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE). The diversity-based certifications, appointed by the National Minority Supplier...
Nexus Pharmaceuticals Announces Great Place to Work® Certification

Nexus Pharmaceuticals Announces Great Place to Work® Certification

by Deana Mndrucic | Dec 2, 2020 | News

LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute for a second consecutive year. For the second year in a row, at least 76% of Nexus employees have attested that the...
Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP

Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP

by Alicen Baran | Oct 29, 2020 | News, Product Approvals

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥....
Nexus Pharmaceuticals Named One of the 2020 Best Workplaces in Chicago by Great Place to Work®

Nexus Pharmaceuticals Named One of the 2020 Best Workplaces in Chicago by Great Place to Work®

by Diana Lebiecki | Jun 15, 2020 | News

The Great Place to Work® Institute has honored Nexus Pharmaceuticals as one of the 2020 Best Workplaces in Chicago. The ranking considered over 27,000 responses from Chicago area employees. Great Place to Work, a global people analytics and consulting firm, evaluated...
« Older Entries